AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 42 min read$REPL

Sarchi Christopher sold $111K of REPL

Sarchi Christopher (Chief Commercial Officer) sold 12,000 shares of Replimune Group, Inc. (REPL) at $9.24 ($0.11M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sarchi Christopher
Published Jun 4, 2026, 12:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLNeutralLow
01

Why it matters

The disclosure updates the insider activity record but does not introduce new operational/financial information about the company.

02

Market read

Traders may monitor for sentiment drift or additional insider activity, but the 10b5-1 framing limits immediate fundamental read-through.

03

What to watch

The article provides only the sale size/price and 10b5-1 status; it does not indicate whether other insiders sold, whether the plan is part of routine scheduled sales, or any concurrent news.

Relevance 6/10Novelty 3/10Timing: Filed June 3; sale executed June 1 (after-hours disclosure window).

Background

This is an SEC Form 4 insider transaction disclosure (open-market sale) by a named executive of Replimune Group, Inc.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

SEC Form 4 shows CCO Sarchi Christopher sold 12,000 shares of Replimune Group at $9.24 on a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; watch for follow-on selling or unusual volume around the filing date.

Evidence & confidence

The filing is an ownership-change disclosure with no accompanying company-specific fundamental catalyst; 10b5-1 reduces interpretive weight.

Market effects

Sector

Minimal—single-company insider transaction without sector-wide signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider sales can precede periods of weaker fundamentals; traders may treat it as a caution flag if paired with other negative signals.

Key entities

  • issuer
    Replimune Group, Inc.

    Subject of the insider transaction disclosure; CCO sold shares under a 10b5-1 plan.

  • insider
    Sarchi Christopher

    Chief Commercial Officer who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

REPL insider trading history →

Related articles

OCT 28
$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.

tradingview.com1 min
OCT 28
$REPLMed

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m.

SEC EDGAR 8-K2 min
OCT 1
$REPLHighAI 8/10

Replimune launches melanoma therapy in US market

Replimune Group Inc. (REPL) announced the U.S. commercial launch of TUDRIQEV, a melanoma therapy for advanced cutaneous melanoma patients who progressed on PD-1-blocking treatments. The FDA granted accelerated approval based on a 24.2% objective response rate in trials. The company estimates 105,000 new U.S. melanoma cases in 2025. Continued approval depends on confirmatory trial results.

investing.com2 min
OCT 1
$REPLHighAI 8/10

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

Replimune Group, Inc. (REPL) announced that TUDRIQEV™, a treatment for advanced melanoma, is now available in the U.S. The therapy, approved under accelerated approval, is indicated for adult patients who have progressed with PD-1-blocking antibody regimens. TUDRIQEV achieved a 24.2% objective response rate in clinical trials, with a median duration of 14.1 months. The company also launched a patient support program to assist with access and reimbursement.

globenewswire.com2 min